Voclosporin Q&A summary slide_final 17 Jan 2022.pdf (363.47 kB)
Download file

Voclosporin in lupus nephritis: a profile of its use

Download (363.47 kB)
online resource
posted on 16.01.2022, 18:23 by Esther S. Kim, Susan J. Keam
Acknowledgements
The manuscript was reviewed by: S Mirkov, University of Otago School of Pharmacy, Dunedin, New Zealand; A. Singh, All India Institute of Medical Sciences Raipur, Raipur, Chhattisgarh, India;. During the peer review process, Aurinia Pharmaceuticals, the marketing authorization holder of voclosporin, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest E. S. Kim is a contracted employee of Adis International Ltd/Springer Nature and S.J. Keam is a salaried employee of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Additional information about this Adis Drug Review can be found here.

Abstract
Voclosporin (Lupkynis™), a novel calcineurin inhibitor, is effective as an add-on to background immunosuppressive therapy in adults with active lupus nephritis. Voclosporin, in combination with mycophenolate mofetil and low-dose steroids, achieved higher complete renal response rates in adults with active lupus nephritis than mycophenolate mofetil and low-dose steroids alone. Voclosporin treatment led to early and sustained reductions in proteinuria. Voclosporin was generally well tolerated, with no unexpected adverse events.

© Springer Nature Switzerland AG 2022


History